Edwards Lifesciences
693 hedge funds and large institutions have $21.4B invested in Edwards Lifesciences in 2016 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 237 increasing their positions, 263 reducing their positions, and 63 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 23 → 33 (+10)
30% more call options, than puts
Call options by funds: $114M | Put options by funds: $87.6M
19% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 63
18% more capital invested
Capital invested by funds: $18.1B → $21.4B (+$3.33B)
0% more funds holding
Funds holding: 692 → 693 (+1)
0.4% less ownership
Funds ownership: 256.52% → 256.11% (-0.4%)
10% less repeat investments, than reductions
Existing positions increased: 237 | Existing positions reduced: 263
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$163M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$151M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$124M |
| 4 |
Goldman Sachs
New York
|
+$99.5M |
| 5 |
O
OrbiMed
New York
|
+$97.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$185M |
| 2 |
Renaissance Technologies
New York
|
-$83.3M |
| 3 |
HM
HealthCor Management
New York
|
-$67.8M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
-$65.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$64.9M |
EW Hedge Fund Activity: Q3 2016 in Review
693 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2016, worth a combined $21.4B — up 18% from $18.1B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new EW positions and 63 closed out — a net gain of 12 holders — while 237 added to existing stakes and 263 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $163M. The largest seller was Fidelity Investments, cutting an estimated $185M.
- 693 institutional investors held Edwards Lifesciences (EW) as of Q3 2016, up from 692 in Q2 2016.
- Funds reported $21.4B of Edwards Lifesciences stock for Q3 2016, up 18% quarter-over-quarter.
- 75 funds opened new Edwards Lifesciences positions in Q3 2016 and 63 closed out, a net change of +12 holders.
- The largest Edwards Lifesciences buyer in Q3 2016 was Citadel Advisors, an estimated $163M added.
- The largest Edwards Lifesciences seller in Q3 2016 was Fidelity Investments, an estimated $185M sold.
Based on aggregated 13F filings for Q3 2016.